Shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) dropped 3.7% during mid-day trading on Tuesday . The stock traded as low as $2.06 and last traded at $2.09, with a volume of 927,020 shares trading hands. The stock had previously closed at $2.17.

DNAI has been the topic of several research analyst reports. SunTrust Banks Inc. lowered ProNAi Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $25.00 to $4.00 in a research note on Monday, June 6th. Wedbush lowered ProNAi Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Monday, June 6th. Jefferies Group lowered ProNAi Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the company from $22.00 to $4.50 in a research note on Monday, June 6th. Finally, Zacks Investment Research lowered ProNAi Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. ProNAi Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $17.35.

The firm has a 50-day moving average price of $2.53 and a 200 day moving average price of $5.99. The stock’s market cap is $62.16 million.

ProNAi Therapeutics (NASDAQ:DNAI) last issued its earnings results on Tuesday, May 10th. The company reported ($0.35) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.07. Equities research analysts expect that ProNAi Therapeutics Inc. will post ($1.33) EPS for the current year.

A hedge fund recently bought a new stake in ProNAi Therapeutics stock. Jennison Associates purchased a new position in shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 150,381 shares of the company’s stock, valued at approximately $3,086,000. Jennison Associates owned approximately 0.50% of ProNAi Therapeutics at the end of the most recent quarter.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.